Envision Pharma Group announces appointment of Dr. Deepti Sodhi Jaggi to Board of Directors

Envision Pharma Group (Envision) has appointed Dr. Deepti Sodhi Jaggi to the Envision Board of Directors

“We are pleased to welcome Deepti to the Envision Board of Directors,” shares Meg Heim, CEO of Envision Pharma Group. “Deepti’s deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner.” 

Dr. Jaggi’s career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan.

Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies.

Dr. Jaggi’s previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area.

“I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives,” says Dr. Jaggi. 

Dr. Jaggi’s educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business. 

Close

Envision Pharma Group (Envision) has appointed Dr. Jennifer Costello, PharmD, BCPS, CMPP to the role of Chief Medical Officer. Jennifer will be responsible for progressing work across all sectors of Envision’s business including Technology, Medical, Commercial, Public Affairs, and Value & Access and Data Analytics.

Meg Heim, CEO of Envision Pharma Group, adds, “I am so excited to welcome Jennifer to the Envision team as Chief Medical Officer. Jennifer’s deep expertise in science, and commercialization in the life sciences industry, in addition to her extensive pharmaceutical understanding and experience will further support the acceleration of our business expansion, mission, and commitment to our vision as a technology-enabled partner to the life sciences industry.”

Jennifer is an accomplished pharmaceutical and healthcare leader with over 20 years of experience across the healthcare sector. She brings to this role extensive cardiovascular, medical, and patient care-related focused expertise, with a successful track record of leading high-performing cross-matrix teams with global impact.

Prior to joining Envision, Jennifer held multiple leadership roles in global medical affairs and publications, US HEOR publications, and global scientific content. She developed a reputation for leading successful partnerships with cross functional colleagues, advocacy partners, and academic groups that resulted in building innovative programs that foster healthcare transformation. 

Jennifer joins Envision from Bristol Myers Squibb where she most recently led cardiovascular (CV) patient advocacy across its CV portfolio (early phase assets to marketed products). She drove the development and execution of global and US strategies for a successful launch of a first-in-class CV asset, working across early asset development, commercial, and medical affairs teams. For her work in this space, she was awarded the coveted “Innovation Award” from BMS.

Before joining the pharmaceutical industry, her 16 years of experience as a practicing clinical pharmacist was within the academic medical-teaching hospital. Jennifer served in numerous roles as a pediatric critical care specialist, adult ambulatory clinical care specialist, hospital administrator, and as a Director of Clinical Pharmacy Services. Under a collaborative practice agreement, she also led outpatient care optimization, directly co-managing heart failure, antithrombotic, and diabetic patients. 

Jennifer received her PharmD from Northeastern University, completed her ASHP PGY-1 residency at the University of Arizona/University Medical Center, and received her board certification as a pharmacotherapy specialist from the American College of Clinical Pharmacy. She served in adjunct teaching positions with Rutgers University (where she continues to be a visiting professor) and the University of Florida. She has authored over 50 publications and posters and served as a pharmacy national thought leader within the heart failure, antithrombotic, and diabetes management space. 

Jennifer adds, “I am delighted and humbled to join the Envision team during this transformative time. I am looking forward to meeting and working with our Envision family, customers, and partners. This is an exciting period for our industry at large, and I am privileged to build upon our company vision, award-winning technology, and innovation as medical affairs and global healthcare communication leaders.”

Close

Envision Pharma Group (Envision) has appointed Mike Glover as Senior Vice President, Payer and HTA Solutions. Mike will be responsible for leading and developing Envision’s distinctive market access and HTA strategies for early-stage and late-stage businesses, combining customer insights, vision, and creativity. Mike’s key focus areas will be transformations in patient access, global pricing strategies, real world evidence, and improving patient outcomes.

Meg Heim, CEO of Envision Pharma Group, shares, “I am excited to welcome Mike to the team at Envision as Senior Vice President, Payer and HTA Solutions. As we continue to accelerate Envision’s business expansion, mission, and commitment to our clients’ needs, Mike’s extensive experience in developing and implementing cutting-edge access, policy, and pricing strategies while executing fully integrated market access programs will be critical in partnering with our clients to accomplish their goals, improve performance, and meet their unique business needs with the support of our technology platforms.”

Prior to joining Envision, Mike served as Vice President, Head of Global Access and Pricing Strategy for GlaxoSmithKline. Before that, he held various leadership positions of increasing responsibility there and at Sanofi and Bristol Myers Squibb. He brings with him a diverse background spread across multiple geographies, functions, and therapeutic areas with global commercial leadership experience spanning oncology, cardiovascular, diabetes, and virology – from asset development to in-market delivery, which will be a valuable asset to Envision.

Mike adds, “The energy and passion of the Envision team shines through in every interaction I've had. It was this passion and desire to be the very best at what they do that made this an easy decision for me to join Envision. Our industry is facing a changing and challenging environment and Envision is building an organization that will not just deliver, but will become a true partner for our customers adding real value across the life cycle of a brand. I am delighted to be joining them at this important time in our industry’s future." 

Close

Envision Pharma Group (Envision) has appointed Tino Quintero to the role of General Manager/VP of Market Access & Customer Insights.

Tino will be responsible for collectively driving Envision’s capability building, client and business development, client servicing, and project execution, as well as staff development and mentorship for the Market Access & Customer Insights teams. 

Meg Heim, CEO of Envision Pharma Group, shares, “I am so excited to welcome Tino to the Envision team as General Manager/VP of Market Access & Customer Insights. Tino’s depth of expertise and proven leadership capabilities in market access will drive Envision’s market access strategy as we continue to solidify our leadership and proficiency in the value and access and data analytics space. Tino will further support the acceleration of our business expansion, mission, and commitment to our vision as a technology-enabled partner to the life sciences industry.”

Tino has over 25 years of demonstrated success as a biopharma and life sciences executive. He possesses broad experience in global commercial strategy, market and value access, and business development at Sarepta Therapeutics, Gilead, Vertex, AbbVie, and Syneos. He has been instrumental in the launch and commercialization of numerous products in various therapeutic areas, including cell and gene therapy, rare diseases, oncology, and infectious and autoimmune diseases. He has a consistent and proven track record of success in building, leading, and executing corporate goals.

Tino joins Envision from The Q Group, where as a founder, he advised executive leaders on critical operational and strategic areas for cell and gene therapy, mental health, and healthcare software companies. Prior to this, he was Chief Commercial Officer at Locus Biosciences where he led commercial strategy for the company’s early-stage pipeline assets, human resources, and strategic partnerships. Tino developed a go-to-market plan to secure Series B fundraising, corporate strategic leadership, and management of alliance partnerships. 

Tino adds, “I am very fortunate to join the Envision Pharma Group team during this exciting time of growth. We are leveraging data, technology, and our teams’ experience to address customers’ needs and improve outcomes. I look forward to accelerating our current business while expanding into new markets and engaging new customers.”

Close

Envision Pharma Group is proud to announce its participation at MAPS EMEA 2023 in Lisbon. Set to take place between May 14–16, the conference will bring together some of the brightest minds in the industry to share insights, exchange ideas, and discuss the latest developments and industry breakthroughs. 

Our team of experts will be on hand to communicate its knowledge and expertise, so get ready to meet Dawn Lobban, Elizabeth Perdeaux, Trevor Fitzpatrick, and Andrew Thompson.

See the full meeting agenda via the button below and follow us on social media for live updates and exclusive behind-the-scenes content.   

We look forward to sharing our insights and experiences with the broader medical affairs community! 

MAPS EMEA Agenda

Close

Envision Pharma Group (Envision) has appointed Richard “Rich” Gorman to the role of President, Strategic Consulting and member of the Executive Leadership Team.

Rich is a 30-year veteran of the life sciences industry and a respected leader with a track record of success in pharmaceutical commercialization. He is an experienced head of high-performing teams that build go-to-market strategies to deliver on business development and revenue generation goals.

Rich will be responsible for leading the Strategic Consulting business across Envision’s commercial, medical, and technology sectors. He will lead a team of scientific, medical, and commercial strategists with deep expertise in the life sciences industry while combining its technology and AI platforms to accelerate the business and scientific momentum of clients’ strategies.

Prior to joining Envision, Rich served as Chief Commercial Officer and Global Head of Strategy for Amplity Health. Before that, he held various leadership positions and senior business development roles at Syneos Health. His background includes serving as a CEO for a specialty pharmaceutical company, as well as several positions within the field of contract pharmaceutical development and manufacturing.

Rich shares, “I am delighted to be joining Envision Pharma Group at this pivotal and exciting time. I am honored to have the opportunity to lead this talented team of strategy consultants. Combining their proven capabilities with the Envision technology platform will create a powerful option for manufacturers looking to efficiently bring new science and products to patients.”  

Meg Heim, Chief Executive Officer of Envision Pharma Group states, “We are so excited to have Rich join our team as we continue to accelerate Envision’s business expansion, mission, and commitment to our clients’ needs. Rich’s proven expertise will be critical in partnering with our clients to execute upon their goals, improve performance, and meet their unique business needs with the support of our technology platforms and strategic advisory expertise.”

Close

Envision Pharma Group (Envision) has appointed James “Jim” Streeter to the role of President of Technology, CTO and member of the Executive Leadership Team.

Jim is a global growth strategist, transformational change catalyst, and next-generation life sciences technology executive with over 20 years’ experience driving breakthrough strategies, products, and services for top pharmaceutical companies, CROs, biotech innovators, and healthcare organizations. 

Jim will lead Envision’s global technology-enabled commercialization strategy and vision and be responsible for delivering upon its technology and innovation goals. He will oversee the overall efficiency and effectiveness of technology operations/systems and accelerate the delivery of innovative solutions and platforms for enhancements and synergies across Envision to support clients across the globe.

Prior to joining Envision, Jim served as Global Vice President at Oracle Health Sciences where he was responsible for driving development of the eClinical platform, launching new functionalities, expanding APAC market adoption, and leading key aspects of M&A product due diligence. Before Oracle, Jim served in multiple executive director roles at Pharmaceutical Product Development (PPD), assuming full leadership over electronic data capture, IT systems development, IT business engagement and delivery, eClinical strategy, and innovation. 

Jim shares, “I am excited to be joining Envision at such an important time for the company and the life sciences industry. There is a clear opportunity for Envision’s award-winning technology and people to increase its value to our customers and to life sciences. I am looking forward to accelerating Envision’s value through technology and innovation and engaging with its people, customers, and partners.” 

Meg Heim, Chief Executive Officer of Envision Pharma Group shares, “I am so excited to welcome Jim to the Envision team as our new President of Technology, CTO. Jim’s expertise will contribute directly to our foundational technology focus while accelerating our vision as a technology-enabled commercialization partner to the life sciences industry. This new and expanded role is instrumental to the fulfillment of our business expansion, mission, and commitment to our vision of leveraging innovative technology to support our clients.” 

Close

Envision Pharma Group is an exhibitor and Champion sponsor at the 19th Annual Meeting of ISMPP that is taking place from April 23–26 in Washington DC, USA.   

The meeting theme at this event is “Patients First” – so we are delighted to have great representation from our Envision the Patient team (Dawn Lobban, Catherine Elliott, Jacqui Oliver, and Amanda Boughey) who will be participating in plenary sessions, roundtables, and a workshop. Come and meet the team at booth #15 to discover how we connect our world-leading technology solutions with powerful scientific communications, driven by improving patient outcomes everywhere.

For a demonstration of how our technology solutions simplify collaborative reviews for research through services such as iEnvision® and doDOC®, or to find out more about what we can do, send a message to MeetMe@envisionpharma.com. 

We will be providing updates before, during, and after the event and sharing these through our social media page and this event web page, so check back soon. To read our insights from the European Meeting of ISMPP 2023, please click the button below. 

ISMPP EU 2023 Roundup

Close

We are proud to be an exhibitor and sponsor at the MAPS 2023 Global Annual Meeting on March 26–29 in Nashville. 

Meet the Envision team (Kim Cline, Christy Iannelli, Leif Masvaer, Jejett Miller, Brendan Fitzgerald, Francine Carrick, Synnove Smeets, Susanne Clark, Howard Miller, Morag Chambers, Emily Howman, and Kimberly Cash) at booth #14. 

Learn more about our services or request a meeting with the team at MeetMe@envisionpharma.com. 

We will be providing updates before, during, and after the event and will be sharing these through our social media page and this event web page, so check back soon. For the MAPS meeting schedule, click the button below. 

MAPS 2023 Global Meeting Schedule

 

Close

Envision Pharma Group (Envision) has appointed Pauline Bernard to the position of Regional Head, Commercial Strategy, Japan Asia-Pacific (JAPAC).

Pauline will help drive Envision’s global leadership as a technology-enabled commercialization, data analytics, and integrated medical capabilities and solutions partner to the life sciences industry. In her new position, she will be responsible for leading the development of Envision’s growth path throughout the JAPAC region.

With over 30 years of experience working in healthcare in JAPAC, Pauline brings a wealth of knowledge to the organization in this new role. Prior to joining Envision she has worked across several commercial and leadership functions within the top multinational pharmaceutical companies, and most recently in a management consulting practice with a focus on digital technology.

At Envision Pauline will lead its Tokyo and Sydney offices that have supported the JAPAC region and the organization’s global customers for many years. Pauline shares, “I am excited to join Envision at this moment in time and take part in the journey to integrate and seize the full potential of our products and services, while delivering positive outcomes for our clients and patients like we have never done before.”

Meg Heim, Chief Executive Officer of Envision Pharma Group, adds, “Pauline joining the Envision team is another layer in our strategic business expansion. With our legacy of tech-enabled commercialization, value and access and data analytics, and our medical capabilities and solutions for the life sciences industry, this new role is critical to the fulfillment of our business strategy and client success model supporting our clients in the JAPAC region, as well as across the globe to deliver 24-hour support to meet client needs.

“With our recent acquisition of OKRA.ai, now an Envision Pharma Company, we continue to enhance our innovative technology footprint while acquiring leading industry talent that supports our culture and people strategy for our internal and external customers.” 

 

Close

Envision Pharma Group is attending the MAPS webinar "Medical Affairs Contribution to an Integrated Omnichannel Strategy: Let's Get Started" on February 24. 

Kathryn Coles, Global Director Experimental Innovation at Envision Pharma Group, is moderating this discussion where panelists will share their insights on omnichannel considerations in medical affairs, including:

• A brief overview of omnichannel in medical affairs
• The critical components to achieving excellence in an omnichannel approach

We will be sharing a recording of the event once it’s available, so do check back soon.

Close

Envision Pharma Group (Envision), a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced today it has acquired OKRA.ai, an award-winning technology company active in the provision of artificial intelligence (AI) solutions with services across commercialization, real-world evidence and data analytics, medical, and pricing for the pharmaceutical and life sciences industry.

OKRA.ai’s AI products and solutions translate large clinical, scientific, and commercial data sets into actionable insights to empower decision-making and positive outcomes to clients in the life sciences industry.

“We are delighted to welcome OKRA.ai into the Envision family,” shares Meg Heim, CEO, Envision Pharma Group. “The acquisition of OKRA.ai marks an exciting milestone in Envision’s evolution as we continue to accelerate and deliver a compelling combination of technology-enabled capabilities and solutions to clients. The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence expertise enables us to strengthen our offerings to clients across the product life cycle, but more importantly support patients in their journey to health and wellness.” 

Dr. Loubna Bouarfa, founder of OKRA.ai, will be joining Envision as a member of its Executive Leadership Team. Recently, Loubna won the prestigious Deloitte Fast 50 Women in Leadership Award and Forbes 50 Top Women in Tech. Loubna shares, “Today is a redefining moment for OKRA.ai. I am honored to be joining forces with Envision and to see the enormous opportunities for the growth of our combined expertise and solutions for clients in the life sciences industry. As part of Envision Pharma Group, we can accelerate our work to bring AI to the heart of decision-making across the life sciences industry. Our success will not only bring commercial benefit to clients, but lead to improved patient outcomes across the globe.” 

Based in the UK and Netherlands, OKRA.ai employs around 30 members of staff. The acquisition of OKRA.ai will bring the total number of Envision Pharma Group to 1400+ employees across four continents. 

Close